Literature DB >> 18758463

Kras regulatory elements and exon 4A determine mutation specificity in lung cancer.

Minh D To1, Christine E Wong, Anthony N Karnezis, Reyno Del Rosario, Roberto Di Lauro, Allan Balmain.   

Abstract

Kras is the most frequently mutated ras family member in lung carcinomas, whereas Hras mutations are common in tumors from stratified epithelia such as the skin. Using a Hras knock-in mouse model, we demonstrate that specificity for Kras mutations in lung and Hras mutations in skin tumors is determined by local regulatory elements in the target ras genes. Although the Kras 4A isoform is dispensable for mouse development, it is the most important isoform for lung carcinogenesis in vivo and for the inhibitory effect of wild-type (WT) Kras on the mutant allele. Kras 4A expression is detected in a subpopulation of normal lung epithelial cells, but at very low levels in lung tumors, suggesting that it may not be required for tumor progression. The two Kras isoforms undergo different post-translational modifications; therefore, these findings can have implications for the design of therapeutic strategies for inhibiting oncogenic Kras activity in human cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18758463      PMCID: PMC2654781          DOI: 10.1038/ng.211

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  30 in total

Review 1.  Ras proteins: different signals from different locations.

Authors:  John F Hancock
Journal:  Nat Rev Mol Cell Biol       Date:  2003-05       Impact factor: 94.444

2.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.

Authors:  L Johnson; K Mercer; D Greenbaum; R T Bronson; D Crowley; D A Tuveson; T Jacks
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

Review 3.  Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets.

Authors:  Panagiotis A Konstantinopoulos; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Nat Rev Drug Discov       Date:  2007-07       Impact factor: 84.694

4.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

5.  Wildtype Kras2 can inhibit lung carcinogenesis in mice.

Authors:  Z Zhang; Y Wang; H G Vikis; L Johnson; G Liu; J Li; M W Anderson; R C Sills; H L Hong; T R Devereux; T Jacks; K L Guan; M You
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

6.  LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer.

Authors:  Jie Li; Zhongqiu Zhang; Zunyan Dai; Christoph Plass; Carl Morrison; Yian Wang; Jonathan S Wiest; Marshall W Anderson; Ming You
Journal:  Oncogene       Date:  2003-02-27       Impact factor: 9.867

7.  Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice.

Authors:  Hiroki Nagase; Jian-Hua Mao; Allan Balmain
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

8.  Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis.

Authors:  Charles E Patek; Mark J Arends; William A H Wallace; Feijun Luo; Suzanne Hagan; David G Brownstein; Lorraine Rose; Paul S Devenney; Marion Walker; Sarah J Plowman; Rachel L Berry; Walter Kolch; Owen J Sansom; David J Harrison; Martin L Hooper
Journal:  Exp Cell Res       Date:  2007-11-17       Impact factor: 3.905

9.  While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable.

Authors:  Sarah J Plowman; D James Williamson; Maureen J O'Sullivan; Jennifer Doig; Ann-Marie Ritchie; David J Harrison; David W Melton; Mark J Arends; Martin L Hooper; Charles E Patek
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

10.  p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation.

Authors:  Juan José Ventura; Stephan Tenbaum; Eusebio Perdiguero; Marion Huth; Carmen Guerra; Mariano Barbacid; Manolis Pasparakis; Angel R Nebreda
Journal:  Nat Genet       Date:  2007-04-29       Impact factor: 38.330

View more
  62 in total

Review 1.  How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.

Authors:  Ethan J Brock; Kyungmin Ji; John J Reiners; Raymond R Mattingly
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

2.  Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Authors:  Craig M Bielski; Mark T A Donoghue; Mayur Gadiya; Aphrothiti J Hanrahan; Helen H Won; Matthew T Chang; Philip Jonsson; Alexander V Penson; Alexander Gorelick; Christopher Harris; Alison M Schram; Aijazuddin Syed; Ahmet Zehir; Paul B Chapman; David M Hyman; David B Solit; Kevin Shannon; Sarat Chandarlapaty; Michael F Berger; Barry S Taylor
Journal:  Cancer Cell       Date:  2018-11-01       Impact factor: 31.743

Review 3.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

4.  K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif.

Authors:  Frederick D Tsai; Mathew S Lopes; Mo Zhou; Helen Court; Odis Ponce; James J Fiordalisi; Jessica J Gierut; Adrienne D Cox; Kevin M Haigis; Mark R Philips
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

5.  TPL2 kinase is a suppressor of lung carcinogenesis.

Authors:  Katerina Gkirtzimanaki; Kalliopi K Gkouskou; Urszula Oleksiewicz; Georgios Nikolaidis; Dimitra Vyrla; Michalis Liontos; Vassiliki Pelekanou; Dimitris C Kanellis; Kostantinos Evangelou; Efstathios N Stathopoulos; John K Field; Philip N Tsichlis; Vassilis Gorgoulis; Triantafillos Liloglou; Aristides G Eliopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

6.  Rare codons regulate KRas oncogenesis.

Authors:  Benjamin L Lampson; Nicole L K Pershing; Joseph A Prinz; Joshua R Lacsina; William F Marzluff; Christopher V Nicchitta; David M MacAlpine; Christopher M Counter
Journal:  Curr Biol       Date:  2012-12-13       Impact factor: 10.834

7.  miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1.

Authors:  Zhiju Zhao; Limei Qin; Shu Li
Journal:  Tumour Biol       Date:  2015-11-17

Review 8.  A New View of Ras Isoforms in Cancers.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Mayukh Chakrabarti; Hyunbum Jang
Journal:  Cancer Res       Date:  2015-12-10       Impact factor: 12.701

9.  Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis.

Authors:  Thomas LaFramboise; Ninad Dewal; Katherine Wilkins; Itsik Pe'er; Matthew L Freedman
Journal:  PLoS Genet       Date:  2010-09-02       Impact factor: 5.917

10.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

Authors:  Ann Marie Egloff; Jennifer Rubin Grandis
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.